The DOI matches its Crossref record; 31 of the 34 references it cites were found in a registry or an index.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Abstract
Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.Methods We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centres in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harbouring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimisation technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m(2), intravenously) plus docetaxel (60 mg/m(2), intravenously; n=89), administered every 21 days for three to six cycles. The primary endpoint was progression-free survival. Survival analysis was done with the modified intention-to-treat population. This study is registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.Findings Five patients were excluded (two patients were found to have thyroid and colon cancer after randomisation, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel). Thus, 172 patients (86 in each group) were included in the survival analyses. The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel goup, with a median progression-free survival time of 9.2 months (95% CI 8.0-13.9) versus 6.3 months (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001). Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhoea were more frequent in the gefitinib group. Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.Interpretation Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.Funding West Japan Oncology Group (WJOG): a non-profit organisation supported by unrestricted donations from several pharmaceutical companies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“have shown improved efficacy and tolerability compared with chemotherapy in numerous phase III trials”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [30]
In the citing paper
“In clinical trials, the incidence of all-grade liver injury due to different smallmolecule targeted drugs such as tyrosine kinase inhibitors is reportedly 5-55% [144-149].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [145]
In the citing paper
“Eight randomised controlled phase III trials (table 1) have demonstrated that first-generation or second-generation EGFR-TKIs represent the best first-line treatment option in patients with advanced NSCLC whose tumours harbour EGFR mutations, when compared with chemotherapy, because they significantly improved the RR and progression-free survival (PFS).4–11”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [5]
In the citing paper
“Unfortunately, whilst patients with EGFRm+ tumors typically show good initial responses to first generation TKIs, most patients who respond to therapy ultimately develop disease progression after about 9-14 months of treatment (7-11).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [8]
In the citing paper
“Most patients whose tumors harbor exon 19 deletions or L858R EGFR activating mutations have radiographic responses to monotherapy with the reversible adenosine triphosphate (ATP)-competitive EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib 17–23 and the irreversible EGFR TKI afatinib 24.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [21]
In the citing paper
“Several randomized clinical trials have demonstrated that EGFR TKIs are more effective, as measured by response rate (RR) and progression free survival (PFS), than chemotherapy when used as initial systemic treatment for advanced EGFR mutant NSCLC (1, 4–9).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [9]
In the citing paper
“Several other trials conducted in Asia confirmed the superiority of Gefitinib over chemotherapy in EGFR-mutated patients [16, 44, 64].”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [16]
In the citing paper
“Targeted therapies for these lung cancers were established based on 7 phase III randomized trials.5, 6, 7, 8, 9, 10, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Randomized phase III trials have demonstrated the superiority of these TKI, in terms of progression free survival (PFS), to conventional chemotherapy in patients with lung cancers harboring EGFR mutations.5, 6, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Evidence of these common mutations has been developed in prospective trials: gefitinib, erlotinib and afatinib showed ORR of approximately 60% and PFS of 9–13 months.5, 6, 7, 8, 9, 10, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [6]
In the citing paper
“Several studies have consistently demonstrated that the EGFR TKIs (gefitinib, erlotinib and afatinib) produce higher RRs, longer PFS and improve QoL compared with standard platinum-based doublet chemotherapy in patients with good PS (PS 0-2), whose tumour harbours an activating (sensitising) EGFR mutation [105-112].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [109]
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationComparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Self-citationKris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,435
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Research works printed but not linked: 2
- Cappuzzo, 2009, Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study, J Thorac Oncol, 4
- Lee, 2009, A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung, J Thorac Oncol, 4
Cited by
Sorted by citations
Items 901–1,000 of 1,010
Pietanza, M. C., Gadgeel, S. M., Dowlati, A., Lynch, T. J., Salgia, R., Rowland, K. M., Wertheim, M. S., Price, K. A. R., Riely, G. J., Azzoli, C. G., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824c943f · Cited by 46
Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Treatment
Moran, C. A. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.057 · Cited by 46
Amplification of TRIM44: Pairing a Prognostic Target With Potential Therapeutic Strategy
Ong, C. J., Shannon, N. B., Ross-Innes, C. S., O’Donovan, M., Rueda, O. M., Hu, D., Kettunen, M. I., Walker, C., Noorani, A., Hardwick, R. H., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju050 · Cited by 46
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
Rothschild, S. I., & Gautschi, O. P. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.006 · Cited by 46
Kapp, J. R., Diss, T. C., Spicer, J. F., Gandy, M., Schrijver, I., Jennings, L. J., Li, M. M., Tsongalis, G. J., de Castro, D. G., Bridge, J. A., et al. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202644 · Cited by 46
Asahina, H., Oizumi, S., Inoue, A., Kinoshita, I., Ishida, T., Fujita, Y., Sukoh, N., Harada, M., Maemondo, M., Saijo, Y., et al. (2010) · Oncology · doi:10.1159/000326488 · Cited by 46
Dai, J., Shi, J., Soodeen-Lalloo, A. K., Zhang, P., Yang, Y., Wu, C., Jiang, S., Jia, X., Fei, K., & Jiang, G. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.009 · Cited by 46
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44
Zhu, Q., Sun, Y., Cui, Y., Ye, K., Yang, C., Yang, D., Ma, J., Liu, X., Yu, J., & Ge, H. (2017) · Oncotarget · doi:10.18632/oncotarget.14515 · Cited by 46
Reckamp, K. L., Frankel, P. H., Ruel, N. H., Mack, P. C., Gitlitz, B. J., Li, T., Koczywas, M., Gadgeel, S. M., Cristea, M. C., Belani, C. P., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00132 · Cited by 46
Lee, J., Kim, H. S., Lee, B., Kim, H. K., Sun, J., Ahn, J. S., Ahn, M., Park, K., & Lee, S. (2020) · Cancer · doi:10.1002/cncr.32809 · Cited by 46
Panneerselvam, J., Mohandoss, P., Patel, R., Gillan, H., Li, M., Kumar, K., Nguyen, D., Weygant, N., Qu, D., Pitts, K., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.05.012 · Cited by 46
Targeting EGFR in lung cancer: Lessons learned and future perspectives
Steuer, C. E., & Ramalingam, S. S. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.004 · Cited by 46
The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience
Zeng, X., Karnon, J. D., Wang, S., Wu, B. Y., Wan, X., & Peng, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048323 · Cited by 46
Hosoda, W., Takagi, T. J., Mizuno, N., Shimizu, Y., Sano, T., Yamao, K., & Yatabe, Y. (2010) · Pathology International · doi:10.1111/j.1440-1827.2010.02527.x · Cited by 45
Self-citationLai, Y., Zhang, Z., Li, J., Sun, D. I., Zhou, Y., Jiang, T., Han, Y., Huang, L., Zhu, Y., Li, X., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224549 · Cited by 45
Nanjo, S., Yamada, T., Nishihara, H., Takeuchi, S., Sano, T., Nakagawa, T., Ishikawa, D., Zhao, L., Ebi, H., Yasumoto, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084700 · Cited by 45
Kogure, Y., Ando, M., Saka, H., Chiba, Y., Yamamoto, N., Asami, K., Hirashima, T., Seto, T., Nagase, S., Otsuka, K., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828b51f5 · Cited by 45
Self-citationManagement of Non-Small Cell Lung Cancer with Oligometastasis
Villaruz, L. C., Kubicek, G. J., & Socinski, M. A. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0240-1 · Cited by 45
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
Metro, G., & Crinò, L. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.34 · Cited by 45
Yang, J. C., Wu, Y.-L. L. C., Chan, V. F., Kurnianda, J., Nakagawa, K., Saijo, N., Fukuoka, M., McWalter, G., McCormack, R., & Mok, T. S. K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.021 · Cited by 45
Self-citationSakashita, H., Inoue, H., Akamine, S., Ishida, T., Inase, N., Shirao, K., Mori, M., & Mimori, K. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3059-6 · Cited by 45
Zhao, H., Fan, Y., Ma, S., Song, X., Han, B., Cheng, Y., Huang, C., Yang, S., Liu, X., Liu, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000445 · Cited by 45
Zhang, B., Zhang, Y., Zhao, J., Wang, Z., Wu, T., Ou, W., Wang, J., Yang, B., Zhao, Y. X., Rao, Z., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0127-0 · Cited by 45
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?
Farhat, F. S., & Houhou, W. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013492001 · Cited by 45
Epidermal Growth Factor Receptor–Mutant Lung Cancer
Piotrowska, Z., & Sequist, L. V. D. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000147 · Cited by 45
A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
Cui, G., Liu, D., Li, W., Fu, X., Liang, Y., Li, Y., Shi, W., Chen, X., & Zhao, S. Q. (2017) · Medicine · doi:10.1097/md.0000000000006552 · Cited by 45
Skinner, K. E., Fernandes, A. W., Walker, M. S., Pavilack, M., & Vanderwalde, A. M. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1389744 · Cited by 45
Hattori, A., Takamochi, K., Oh, S., & Suzuki, K. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy142 · Cited by 45
He, Z., Li, M., Lin, J., Lin, D., & Lin, R.-J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s184922 · Cited by 45
Patton, S. J., Normanno, N., Blackhall, F. H., Murray, S. J., Kerr, K. M., Dietel, M., Filipits, M., Benlloch, S., Popat, S., Stahel, R. A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.353 · Cited by 45
Pan, Y., Wang, R., Ye, T., Li, C., Hu, H., Yu, Y., Zhang, Y., Wang, L., Luo, X., Li, H., et al. (2013) · CHEST Journal · doi:10.1378/chest.12-2679 · Cited by 45
Tyrosine Kinase Inhibitors in Lung Cancer
Thomas, A., Rajan, A., & Giaccone, G. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.001 · Cited by 45
RAC 1 inhibition as a therapeutic target for gefitinib‐resistant non‐small‐cell lung cancer
Kaneto, N., Yokoyama, S., Hayakawa, Y., Kato, S., Sakurai, H., & Saiki, I. (2014) · Cancer Science · doi:10.1111/cas.12425 · Cited by 45
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Pallis, A. G., & Syrigos, K. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.025 · Cited by 44
Morán, T., & Sequist, L. V. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1858 · Cited by 44
Su, C., Zhou, F., Shen, J., Zhao, J., & O'Brien, M. E. R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.002 · Cited by 44
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Otsuka, K., Hata, A., Takeshita, J., Okuda, C., Kaji, R., Masago, K., Fujita, S., & Katakami, N. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2867-8 · Cited by 44
Self-citationTogashi, Y., Mizuuchi, H., Tomida, S., Terashima, M., Hayashi, H., Nishio, K., & Mitsudomi, T. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.020 · Cited by 44
Self-citationYamada, T., Takeuchi, S., Kita, K., Bando, H., Nakamura, T., Matsumoto, K., & Yano, S. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182398e69 · Cited by 44
A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene
Tanaka, H., Hayashi, A., Morimoto, T., Taima, K., Tanaka, Y., Shimada, M., Kurose, A., Takanashi, S., & Okumura, K. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-558 · Cited by 44
Kwak, E. L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0087 · Cited by 44
Takeda, M., Yamanaka, T., Seto, T., Hayashi, H., Azuma, K., Okada, M., Sugawara, S., Daga, H., Hirashima, T., Yonesaka, K., et al. (2016) · Cancer · doi:10.1002/cncr.29893 · Cited by 44
Self-citationSesumi, Y., Suda, K., Mizuuchi, H., Kobayashi, Y., Sato, K., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.012 · Cited by 44
Self-citationHidaka, N., Iwama, E., Kubo, N., Harada, T., Miyawaki, K., Tanaka, K., Okamoto, I., Baba, E., Akashi, K., Sasaki, H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.019 · Cited by 44
Self-citationYagi, S., Koh, Y., Akamatsu, H., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Endo, K., Nakamura, S., Higuchi, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179744 · Cited by 44
Tamura, M., Kondo, M., Horio, M., Ando, M., Saito, H., Yamamoto, M., Horio, Y., & Hasegawa, Y. (2012) · PubMed Central · doi:10.18999/nagjms.74.1-2.133 · Cited by 44
Self-citationJavadi, S., Zhiani, M., Mousavi, M. A., & Fathi, M. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151083 · Cited by 44
The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing
Roh, M. H. (2015) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2015.06.16 · Cited by 44
Serizawa, M., Takahashi, T., Yamamoto, N., & Koh, Y. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318279e942 · Cited by 44
Lin, Y.-T., Liu, Y.-N., Wu, S.-G., Yang, J. C.-H., & Shih, J.-Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.014 · Cited by 43
Shimamura, S., Shukuya, T., Asao, T., Hayakawa, D., Kurokawa, K., Xu, S., Miura, K., Mitsuishi, Y., Tajima, K., Shibayama, R., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09421-7 · Cited by 43
Managing Resistance to EFGR- and ALK-Targeted Therapies
Lovly, C. M., Iyengar, P., & Gainor, J. F. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_176251 · Cited by 43
Noguchi, M., Kohno, S., Pellattiero, A., Machida, Y., Shibata, K., Shintani, N., Kohno, T., Gotoh, N., Takahashi, C., Hirao, A., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05768-2 · Cited by 43
Self-citationSuccesses and Limitations of Targeted Cancer Therapy in Lung Cancer
Suda, K., & Mitsudomi, T. (2014) · Progress in tumor research · doi:10.1159/000355902 · Cited by 43
Self-citationLiu, J., Li, W., Gao, S., Wang, F., Li, X., Yu, H., Fan, L., Wei, W., Wang, H., & Sun, G. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.03.006 · Cited by 43
Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
Hayashi, H., Kurata, T., & Nakagawa, K. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s6252 · Cited by 43
Self-citationWeber, B., Hager, H., Sørensen, B. S., McCulloch, T., Mellemgaard, A., Khalil, A. A., Nexø, E., & Meldgaard, P. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.023 · Cited by 43
Okumura, S., Sasaki, T., Minami, Y., & Ohsaki, Y. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318233d686 · Cited by 43
Afatinib for the treatment of metastatic non-small cell lung cancer
Joshi, M., Rizvi, S., & Belani, C. P. (2015) · Cancer Management and Research · doi:10.2147/cmar.s51808 · Cited by 43
de Mello, R. A. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i11.367 · Cited by 43
Zhu, J., Wang, Y., Duan, J., Bai, H., Wang, Z., Wei, L., Zhao, J., Zhuo, M., Wang, S., Yang, L., et al. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-80 · Cited by 43
Yoshida, T., Yamada, K., Azuma, K., Kawahara, A., Abe, H., Hattori, S., Yamashita, F., Zaizen, Y., Kage, M., & Hoshino, T. (2012) · Medical Oncology · doi:10.1007/s12032-012-0349-y · Cited by 43
Saruwatari, K., Ikemura, S., Sekihara, K., Kuwata, T., Fujii, S., Umemura, S., Kirita, K., Matsumoto, S., Yoh, K., Niho, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.012 · Cited by 43
Juan, Ó., & Popat, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687262 · Cited by 43
UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells
Liu, Z., & Xu, L. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.12.138 · Cited by 43
Ho, G. F., Chai, C.-S., Alip, A., Wahid, M. I. A., Abdullah, M. M., Foo, Y. C., How, S.-H., Zaatar, A., Lam, K.-S., Leong, K.-W., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6107-1 · Cited by 43
Vaid, A. K., Gupta, A., & Momi, G. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5168 · Cited by 45
Nakagawa, K., Nadal, E., Garon, E. B., Nishio, M., Seto, T., Yamamoto, N., Park, K., Shih, J., Paz-Ares, L. G., Frimodt‐Moller, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0273 · Cited by 43
Self-citationWang, J., Lam, D., Yang, J., & Hu, L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02952-5 · Cited by 43
Locatelli-Sanchez, M., Couraud, S., Arpin, D., Riou, R., Bringuier, P., & Souquet, P.-J. (2013) · Lung · doi:10.1007/s00408-013-9482-4 · Cited by 43
Conforti, F., Catania, C., Toffalorio, F., Duca, M., Spitaleri, G., Barberis, M. C. P., Noberasco, C., Delmonte, A., Santarpía, M., Lazzari, C., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.019 · Cited by 43
The epidermal growth factor receptor (EGRF) in lung cancer
Carcereny, E., Morán, T., Capdevila, L., Cros, S., Vilà, L., Gil, M. D. L. L., Remón, J., & Rosell, R. (2015) · Translational Respiratory Medicine · doi:10.1186/s40247-015-0013-z · Cited by 44
Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers
Liang, H., Xu, Y., Zhao, J., Chen, M., & Wang, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00761-z · Cited by 45
Hagiwara, K., & Kobayashi, K. (2012) · Cancer Science · doi:10.1111/cas.12081 · Cited by 42
Tan, F., Shi, Y., Wang, Y., Ding, L., Yuan, X., & Sun, Y. P. (2015) · Future Oncology · doi:10.2217/fon.14.249 · Cited by 42
Takeda, M., Okamoto, I., Sakai, K., Kawakami, H., Nishio, K., & Nakagawa, K. (2012) · Annals of Oncology · doi:10.1093/annonc/mds124 · Cited by 42
Self-citationGridelli, C., Rossi, A., Ciardiello, F., de Marinis, F., Crinò, L., Morabito, A., Morgillo, F., Montanino, A., Daniele, G., Piccirillo, M. C., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.04.001 · Cited by 42
Kunimasa, K., Nagano, T., Shimono, Y., Dokuni, R., Kiriu, T., Tokunaga, S., Tamura, D., Yamamoto, M., TACHIHARA, M. Y., Kobayashi, K., et al. (2017) · Cancer Science · doi:10.1111/cas.13266 · Cited by 42
Self-citationStructural insights into drug development strategy targeting EGFR T790M/C797S
Zhu, S., Zhao, P., Yang, J., Ma, R., Yan, X.-E., Yang, S., Yang, J., & Yun, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24113 · Cited by 42
Chang, W.-Y., Wu, Y., Su, P., Yang, S., Lin, C., & Su, W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192161 · Cited by 42
Kujtan, L. A., & Subramanian, J. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1596030 · Cited by 43
Lau, S. C. M., Chooback, N., Ho, C., & Melosky, B. L. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.05.003 · Cited by 42
Wang, S., & Li, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198945 · Cited by 42
Ohba, T., Takamori, S., Toyozawa, R., Nosaki, K., Umeyama, Y., Haratake, N., Miura, N., Yamaguchi, M., Taguchi, K., Seto, T., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.09.29 · Cited by 42
Self-citationYang, J. C., Cheng, Y., Murakami, H., Yang, P., He, J., Nakagawa, K., Kang, J. H., Kim, J.-H., Hozak, R. R., Nguyen, T. S., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.008 · Cited by 42
Self-citationKishikawa, T., Kasai, T., Okada, M., Nakachi, I., Soda, S., Arai, R., Takigami, A., & Sata, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13378 · Cited by 42
Paz-Ares, L. G., Gondos, Á., Saldaña, D., Thomas, M., Mascaux, C., Bubendorf, L., & Barlési, F. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.021 · Cited by 42
Esteban, E., Majem, M., Aguillo, M. M., Martínez-Banaclocha, N., Dómine, M., Gómez-Aldaraví, L., Juan, Ó., Cajal, R., Arenas, M. C. G., & Provencio, M. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.02.003 · Cited by 42
Zhu, H., Cheng, H., Ren, Y., Liu, Z. G., Zhang, Y. F., & Luo, B. D. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-1293-1 · Cited by 42
Niho, S., Ohe, Y., Ishikura, S., Atagi, S., Yokoyama, A., Ichinose, Y., Okamoto, H., Takeda, K., Shibata, T., Tamura, T., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds012 · Cited by 42
Self-citationAkamatsu, H., Inoue, A., Mitsudomi, T., Kobayashi, K., Nakagawa, K., Mori, K. P., Nukiwa, T., Nakanishi, Y., & Yamamoto, N. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt049 · Cited by 42
Self-citationYang, C., Tsai, M., Hung, J., Lee, M., Tsai, Y., Tsai, Y.-C., Hsu, J.-F., Liu, T., Huang, M., & Chong, I. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0190-1 · Cited by 42
Oizumi, S., Sugawara, S., Minato, K., Harada, T., Inoue, A., Fujita, Y., Maemondo, M., Watanabe, S., Ito, K., Gemma, A., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000313 · Cited by 42
Self-citationChiu, C., Chou, T., Chiang, C., & Tsai, C. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2536-3 · Cited by 41
Iwama, E., Sakai, K., Azuma, K., Harada, D., Nosaki, K., Hotta, K., Nishio, M., Kurata, T., Fukuhara, T., Akamatsu, H., et al. (2018) · Cancer Science · doi:10.1111/cas.13820 · Cited by 41
Self-citationHepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
Viganò, M., Milia, M. L., Grassini, M. V., Pugliese, N., Giorgio, M. D., & FAGIUOLI, S. (2023) · Cancers · doi:10.3390/cancers15061766 · Cited by 43
Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41
Lü, S., Ding, D., Yu, Y., Li, Z., & Niu, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s58870 · Cited by 41
Cai, L., Zhu, J., Zhang, X., Lin, S.-X., Su, X., Lin, P., Chen, K., & Zhang, L. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1570-7 · Cited by 41
Metadata
- Authors
- Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., & Fukuoka, M.
- Affiliations
- Aichi Cancer Center (JP)
- Yokohama City University Medical Center (JP)
- Hyogo Prefectural Cancer Center (JP)
- Kindai University (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Osaka City General Hospital (JP)
- Osaka Habikino Medical Center (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
- Kobe City Medical Center General Hospital (JP)
- Kurashiki Central Hospital (JP)
- Kouseiren Takaoka Hospital (JP)
- Osaka City University (JP)
- Tottori University (JP)
- Okayama University (JP)
- Corresponding author
- Mitsudomi, Tetsuya
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 11
- Issue
- 2
- Pages
- 121-128
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2129360604
- Cited by
- 4,090
- References
- 34
- Citations by year
- 2026: 31 · 2025: 110 · 2024: 130 · 2023: 140 · 2022: 211 · 2021: 228 · 2020: 236 · 2019: 264 · 2018: 318 · 2017: 329 · 2016: 312 · 2015: 382 · 2014: 372 · 2013: 352 · 2012: 300
- FWCI
- 187.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Sanofi
- European Society for Medical Oncology
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- gefitinib, non-small cell lung cancer, EGFR mutation, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, progression-free survival, platinum-based chemotherapy, first-line therapy, myelosuppression, postoperative recurrence
- MeSH terms
- Docetaxel, Gefitinib, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Quinazolines, Taxoids, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
